March 31, 2021
Eisai said on March 30 that its multikinase inhibitor lenvatinib (Lenvima) in combination with US Merck’s PD-1 inhibitor pembrolizumab (Keytruda) has been accepted for European regulatory review for additional indications of renal cell carcinoma (RCC) and endometrial carcinoma. The companies...read more